AMSTERDAM, Feb 12 (Reuters) - Dutch biotech firm Crucell CRCL.ASCRXL.O said on Tuesday it expected a significant rise in sales of its Quinvaxem vaccine, which offers protection against five childhood diseases.
“For 2008 we see sales of Quinvaxem significantly higher than in 2007,” Crucell’s Chief executive officer Ronald Brus told analysts but did not give a specific figure.
In 2007 Crucell sold 21.3 million units Quinvaxem, up from 6.3 million in 2006.
The vaccine offers protection against five childhood diseases, including whooping cough was and developed by Berna Biotech, which was bought by Crucell in 2006, and Chiron, now part of Novartis NOVN.VX Vaccines and Diagnostics.
Reporting by Harro ten Wolde